Surfactin Inhibits Osteoclast Differentiation by Negatively Regulating the Elk1-AP-1-NFATc1 Axis
Authors:
- Kazuki MaruyamaKMKazuki Maruyama
- Ayaka KogaAKAyaka Koga
- Yuki KodamaYKYuki Kodama
- Ryota YamasakiRYRyota Yamasaki
- Yoshie Nagai-YoshiokaYNYoshie Nagai-Yoshioka
- Jun J. MiyamotoJMJun J. Miyamoto
- Kayoko KuroishiKKKayoko Kuroishi
- Kaori GunjigakeKGKaori Gunjigake
- Tatsuo KawamotoTKTatsuo Kawamoto
- Wataru AriyoshiWataru Ariyoshi
Open Access
- 11 January 2026
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 155
Abstract
Background/Objectives: Surfactin is a biosurfactant with various biological activities, including antibacterial and anti-inflammatory properties; however, its effects on bone metabolism remain poorly understood. This study aimed to investigate the effects of surfactin on osteoclast differentiation and elucidate its underlying molecular mechanisms. Methods: RAW264.7 cells were treated with receptor activator of nuclear factor-kappa B ligand (RANKL) and surfactin, and osteoclast differentiation and maturation were evaluated by tartrate-resistant acid phosphatase and F-actin staining, respectively. Gene expression of differentiation markers was assessed using real-time reverse transcription-quantitative polymerase chain reaction, while the kinetics of intracellular signaling molecules and transcription factors were analyzed using Western blot analysis. Results: Surfactin treatment significantly inhibited osteoclast differentiation and maturation, as well as the mRNA expression of Nfatc1, Acp5, and Cathepsin K. Although surfactin did not markedly affect RANKL-induced activation of the NF-κB or MAPK-mediated signaling, it significantly suppressed the expression of c-Fos at both the mRNA and protein levels. Furthermore, surfactin attenuated the phosphorylation of Elk1, a transcription factor involved in c-Fos induction. Conclusions: Surfactin inhibits RANKL-induced osteoclast differentiation by negatively regulating the Elk1-AP-1-NFATc1 axis. Surfactin may thus be a promising therapeutic candidate for the treatment of metabolic bone disorders and inflammatory bone destruction.Keywords
Funding Information
- Yoshida Foundation for Academic and Educational Promotion
- Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (21H03145)
- Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (23K21495)
This publication has 49 references indexed in Scilit:
- Molecular Mechanisms of Curdlan‐Induced Suppression of NFATc1 Expression in OsteoclastsJournal of Cellular Biochemistry, 2024
- Physiological and transcriptional profiling of surfactin exerted antifungal effect against Candida albicansBiomedicine & Pharmacotherapy, 2022
- Ameloblastin attenuates RANKL‐mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T‐cell cytoplasmic 1 (NFATc1)Journal of Cellular Physiology, 2018
- Effects of surfactin on membrane models displaying lipid phase separationBiochimica et Biophysica Acta (BBA) - Biomembranes, 2013
- An essential role for the association of CD47 to SHPS-1 in skeletal remodelingJournal of Bone and Mineral Research, 2011
- Osteoclast stimulatory transmembrane protein (OC‐STAMP), a novel protein induced by RANKL that promotes osteoclast differentiationJournal of Cellular Physiology, 2007
- Hemolytic activity of new linear surfactin analogs in relation to their physico-chemical propertiesBiochimica et Biophysica Acta (BBA) - General Subjects, 2005
- Recent trends in the biochemistry of surfactinApplied Microbiology and Biotechnology, 1999
- Induction of c‐fos expression through JNK‐mediated TCF/Elk‐1 phosphorylation.The EMBO Journal, 1995
- Activation of ternary complex factor Elk‐1 by MAP kinases.The EMBO Journal, 1993